High Affinity Binders to EphA2 Isolated from Abdurin Scaffold Libraries; Characterization, Binding and Tumor Targeting

Abdurins are a novel antibody-like scaffold derived from the engineering of a single isolated CH2 domain of human IgG. Previous studies established the prolonged serum half-life of Abdurins, the result of a retained FcRn binding motif. Here we present data on the construction of large, diverse, phag...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 10; no. 8; p. e0135278
Main Authors Ullman, Christopher, Mathonet, Pascale, Oleksy, Arkadiusz, Diamandakis, Agata, Tomei, Licia, Demartis, Anna, Nardi, Chiara, Sambucini, Sonia, Missineo, Antonino, Alt, Karen, Hagemeyer, Christoph E, Harris, Matt, Hedt, Amos, Weis, Roland, Gehlsen, Kurt R
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 27.08.2015
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abdurins are a novel antibody-like scaffold derived from the engineering of a single isolated CH2 domain of human IgG. Previous studies established the prolonged serum half-life of Abdurins, the result of a retained FcRn binding motif. Here we present data on the construction of large, diverse, phage-display and cell-free DNA display libraries and the isolation of high affinity binders to the cancer target, membrane-bound ephrin receptor tyrosine kinase class A2 (EphA2). Antigen binding regions were created by designing combinatorial libraries into the structural loops and Abdurins were selected using phage display methods. Initial binders were reformatted into new maturation libraries and low nanomolar binders were isolated using cell-free DNA display, CIS display. Further characterization confirmed binding of the Abdurins to both human and murine EphA2 proteins and exclusively to cell lines that expressed EphA2, followed by rapid internalization. Two different EphA2 binders were labeled with 64Cu, using a bifunctional MeCOSar chelator, and administered to mice bearing tumors from transplanted human prostate cancer cells, followed by PET/CT imaging. The anti-EphA2 Abdurins localized in the tumors as early as 4 hours after injection and continued to accumulate up to 48 hours when the imaging was completed. These data demonstrate the ability to isolate high affinity binders from the engineered Abdurin scaffold, which retain a long serum half-life, and specifically target tumors in a xenograft model.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Current Address: MRC Technology, London, United Kingdom
Competing Interests: The authors have the following interests. This study was funded and sponsored by Research Corporation Technologies, Inc., the employer of Kurt R. Gehlsen. Christopher Ullman, Pascale Mathonet, Arkadiusz Oleksy and Agata Diamandakis are employed by Isogenica, Ltd., Licia Tomei, Anna Demartis, Chiara Nardi, Sonia Sambucini and Antonino Missineo by IRBM Science Park, Karen Alt and Christoph E. Hagemeyer by Baker IDI, Matt Harris and Amos Hedt by Clarity Pharmaceuticals, Ltd. and Roland Weis by VTU Technology. Research Corporation Technologies, Inc. owns certain patents and patents applications covering the Abdurins and the EphA2 binder, however, there are no products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Conceived and designed the experiments: KRG CU LT MH. Performed the experiments: PM AO A. Demartis A. Diamandakis CN SS AM KA CH AH RW. Analyzed the data: KRG CU PM AO LT A. Demartis CH MH. Contributed reagents/materials/analysis tools: CU PM LT A. Demartis AH RW. Wrote the paper: KRG CU PM A. Demartis KA CH MH RW.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0135278